NVZMF (Novonesis (Novozymes) B) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVZMF Novonesis (Novozymes) B NVZMF
90 GF Score
Price $67.98
GF Value $63.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novonesis (Novozymes) B  (OTCPK:NVZMF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Related Terms


Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.85 5.98 6.37 6.20 6.78

Novonesis (Novozymes) B Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.72 6.52 6.75 6.11 6.36

NVZMF vs LIN, SHW, ECL: Cyclically Adjusted PS Ratio Comparison

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B Cyclically Adjusted PS Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio falls into.


NVZMF
90GF Score
Novonesis (Novozymes) B NVZMF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Novonesis (Novozymes) B's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.784/122.9500*122.9500
=2.784

Current CPI (Jun. 2026) = 122.9500.

Novonesis (Novozymes) B Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.681 100.200 2.063
201612 1.796 100.300 2.202
201703 1.792 101.200 2.177
201706 1.756 101.200 2.133
201709 1.906 101.800 2.302
201712 1.966 101.300 2.386
201803 1.970 101.700 2.382
201806 1.910 102.300 2.296
201809 1.955 102.400 2.347
201812 1.960 102.100 2.360
201903 1.834 102.900 2.191
201906 1.806 102.900 2.158
201909 1.931 102.900 2.307
201912 1.950 102.900 2.330
202003 1.970 103.300 2.345
202006 1.750 103.200 2.085
202009 1.913 103.500 2.272
202012 1.966 103.400 2.338
202103 2.177 104.300 2.566
202106 2.066 105.000 2.419
202109 2.131 105.800 2.476
202112 2.108 106.600 2.431
202203 2.358 109.900 2.638
202206 2.198 113.600 2.379
202209 2.124 116.400 2.244
202212 2.233 115.900 2.369
202303 2.399 117.300 2.515
202306 2.217 116.400 2.342
202309 2.342 117.400 2.453
202312 2.393 116.700 2.521
202403 2.225 118.400 2.311
202406 2.267 118.500 2.352
202409 2.413 118.900 2.495
202412 2.246 118.900 2.323
202503 2.433 120.200 2.489
202506 2.479 120.700 2.525
202509 2.672 121.600 2.702
202512 2.444 121.180 2.480
202603 2.809 121.670 2.839
202606 2.784 122.950 2.784

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of $67.98 is trading 6.5% above its estimated GF Value™ of $63.82. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for NVZMF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $63.82 vs. price of $67.98 (6.5% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score

Get the complete analysis for NVZMF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.98
Price
$63.82
GF Value